Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Uniqure Ord Shs
(NQ:
QURE
)
6.190
-0.315 (-4.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Uniqure Ord Shs
< Previous
1
2
3
4
5
6
Next >
Nordson To Rally Over 14%? Here Are 10 Other Analyst Forecasts For Thursday
June 22, 2023
Chardan Capital cut the price target for uniQure N.V. (NASDAQ: QURE) from $45 to $27. Chardan Capital analyst Matthew Barcus maintained a Buy rating. uniQure shares fell 1.5% to $11.45 in pre-market...
Via
Benzinga
Why UniQure Stock Is Trading Down Today
June 21, 2023
UniQure N.V. (NASDAQ: QURE) shares are lower after the company announced interim data from the Phase I/II trial of AMT-130 in Huntington's Disease.
Via
Benzinga
Crude Oil Rises 2%; LumiraDx Shares Spike Higher
June 21, 2023
U.S. stocks traded lower toward the end of trading, with Nasdaq Composite dropping over 100 points on Wednesday. The Dow traded down 0.04% to 34,040.13 while the NASDAQ fell 0.77% to 13,562.00. The S&P...
Via
Benzinga
Where uniQure Stands With Analysts
June 21, 2023
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
June 21, 2023
From
The Schall Law Firm
Via
Business Wire
Why uniQure Stock Is Crashing Today
June 21, 2023
Investors are focusing on the negative parts of the biotech company's interim results.
Via
The Motley Fool
6 Analysts Have This to Say About uniQure
May 11, 2023
Via
Benzinga
Why ToughBuilt Industries Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
June 21, 2023
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 209.5% to $2.29 after the company signed a Letter of Intention with UAE-Based e-script medicine management company Pharmak...
Via
Benzinga
Nasdaq Tumbles 1%; Patterson Companies Earnings Beat Views
June 21, 2023
U.S. stocks traded mostly lower midway through trading, with Nasdaq Composite dropping over 100 points on Wednesday.
Via
Benzinga
Uniqure Crashes To Six-Year Low On Muddy Results For Huntington's Gene Therapy
June 21, 2023
The company is working on a one-time treatment for Huntington's disease.
Via
Investor's Business Daily
Dow Drops Over 100 Points; Winnebago Industries Posts Downbeat Sales
June 21, 2023
U.S. stocks traded lower this morning, with Dow Jones dropping over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.41% to 33,914.60 while the NASDAQ fell 0.31%...
Via
Benzinga
Analyst Ratings for uniQure
March 07, 2023
Via
Benzinga
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
June 21, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
June 20, 2023
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure's Hemgenix Royalty Sales Agreement Extends Cash Runway, Relieves Near-Term Commercial Risk, Says Analyst
May 15, 2023
uniQure N.V. (NASDAQ: QURE) agreed to sell a portion of the royalty rights due from CSL Behring from Hemgenix (etranacogene dezaparvovec-drbl) net sales to HealthCare Royalty and Sagard Healthcare
Via
Benzinga
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
May 15, 2023
From
uniQure Inc.
Via
GlobeNewswire
Recap: uniQure Q1 Earnings
May 09, 2023
uniQure (NASDAQ:QURE) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:05 AM. Here's what investors need to know about the announcement. Earnings uniQure missed estimated earnings by...
Via
Benzinga
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2023
From
uniQure Inc.
Via
GlobeNewswire
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
March 10, 2023
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per...
Via
Benzinga
uniQure to Participate in Multiple Upcoming Industry Conferences in March
March 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Stock Trying To Close In On Key Technical Measure
February 28, 2023
uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score.
Via
Investor's Business Daily
uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday
February 28, 2023
UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market...
Via
Benzinga
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
February 27, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
February 23, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
February 21, 2023
From
uniQure Inc.
Via
GlobeNewswire
UniQure In-Licenses Early-Stage Amyotrophic Lateral Sclerosis Candidate, Analyst Says Deal Compliments Its Pipeline
January 31, 2023
UniQure N.V. (NASDAQ: QURE) and Apic Bio entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.